Aims and Objectives

• Focus group within the Academy of Pharmaceutical Sciences open to all members with an interest in pulmonary and nasal drug delivery.
• Provide a forum for Industry, Academe and the Regulators to engage in discussion of current issues in science, technology & regulation pertinent to pulmonary and nasal drug delivery.
• Collaborate and coordinate with other relevant organizations active in the field (e.g. Aerosol Society (DDL), EPAG, AAPS,HESI and RDD) with a view to establishing joint meetings and dialogue in the field.
• Provide continuing education for the membership via for e.g. a biennial symposium, interim focussed workshops/seminars.

Focus Group Steering Committee

• Eddie French (Chair), TEKH Consulting Ltd
• Ben Forbes, King’s College London
• Darragh Murnane, University of Hertfordshire
• Jeremy Clarke, GlaxoSmithKline
• John Pritchard, Phillips Respironics
• Joe Takher-Smith, Mylan Global Respiratory Group
• Nayna Govind, NG Pharma Consulting Ltd
• Philippe Rogueda, Watson Pharmaceuticals
• Rob Price, University of Bath

Drugs in the Lungs NETWORK (update with output from DDL 2012)

• The Drugs in the Lung Network was devised with the aim of providing cross-company collaboration and developing industry-academia pre competitive consortia.
• The Network aims to provide supportive for a for technical and scientific (i.e. data rich) discussions with the aim of advancing the knowledge of early - to late stage inhaled product development.
• For more news see the paper from the June 2013 issue of Inhalation Magazine